Epidemiology of Psoriasis and Psoriatic Arthritis

Pérez-Alamino, Rodolfo; Sharlala, Hisham; Adebajo, Ade; Espinoza, Luis R.

doi:10.1007/978-3-319-19530-8_4

Cited by 2 publications

(1 citation statement)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rheumatoid arthritis (RA) tends to be diagnosed later in life and affects females predominantly . Unlike RA, psoriatic arthritis (PsA) and psoriasis (PsO) are equally present in men than women, but are often diagnosed during child‐bearing ages of 30 to 50 years . Ankylosing spondylitis (AS) occurs more frequently in men but also usually peaks between the ages of 20 and 40 years for both men and women.…”

Section: Introductionmentioning

confidence: 99%

Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants

Eworuke

Panucci

Goulding

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Purpose To describe the use of tumor necrosis factor‐alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC). Methods We identified pregnancies among women aged 15 to 54 years between 01/01/2004 and 09/30/2015 from 16 health plans participating in Sentinel. We inferred indication using ICD‐9‐CM codes in the 183‐day period before conception. We assessed proportion of infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab by calendar year, indication, and maternal age, and compared them to proportions in an age‐matched, indication‐matched, and date‐matched non‐pregnant cohort. Results Among 19 681 pregnancies with at least one chronic inflammatory condition, 2990 (15.2%) received a TNFi. In both pregnancies and matched non‐pregnant cohort, TNFi use was highest (34.4%; 55.8%) for PsA patients and lowest (6.2%; 13.4%) for PsO patients. Etanercept was most frequently used among AS/JIA/PsA/PsO/RA patients, while infliximab was the preferred TNFi for CD/UC patients. Except for infliximab and certolizumab, TNFi use during pregnancy decreased after the first trimester. Pregnancies among older pregnant women (45‐54 years) were more likely to be treated compared with the matched non‐pregnant cohort. Conclusion There was a preference for etanercept among pregnancies with AS/JIA/PsA/PsO/RA, despite the availability of other TNFis. Decline in TNFi use after the first trimester may be related to the desire to reduce TNFis transplacental transfer and to minimize infection risk to the fetus or baby associated with live vaccine immunizations after birth.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants

Eworuke

Panucci

Goulding

et al. 2018

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

The Analysis of Serum Vitamin D (25[OH]D) Level in Psoriasis Patients Comparing with Control Subjects

Fernandes

Listiawan

Ervianti

et al. 2020

BIKK

View full text Add to dashboard Cite

Background: Vitamin D has been shown to have an immunomodulatory effect, and previous studies have proven that vitamin D deficiency contributed to several autoimmune diseases, including psoriasis. Purpose: The purpose of this study was to determine serum vitamin D levels in psoriasis vulgaris patients and compare them with control subjects. Methods: The research samples were sixteen adults with psoriasis vulgaris and 16 control subjects. Blood samples were taken, and the serum 25 (OH) D levels were measured using the Chemiluminescent Microparticle Immunoassay method. Result: The mean serum vitamin D in psoriasis vulgaris patients and controls were 14.36 ± 6.36 and 19.92 ± 7.59 ng/mL, respectively. No psoriasis vulgaris were observed in patients with normal 25(OH)D levels, and only 3 control subjects with normal serum 25(OH)D levels. These results were not statistically significant (p = 0.09). Conclusion: Most patients with psoriasis vulgaris were observed having vitamin D deficiency. However, the prevalence of vitamin D deficiency in the control subjects was high as well. Therefore, there were no differences in serum 25(OH)D levels between psoriasis vulgaris and control patients.

show abstract

Epidemiology of Psoriasis and Psoriatic Arthritis

Cited by 2 publications

References 63 publications

Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants

Use of tumor necrosis factor‐alpha inhibitors during pregnancy among women who delivered live born infants

The Analysis of Serum Vitamin D (25[OH]D) Level in Psoriasis Patients Comparing with Control Subjects

Contact Info

Product

Resources

About